EG1
Based on 1 publication(s) in Google Scholar
EG1, a specific Pax2 inhibitor, directly binds the paired domain of Pax2 (Kd=1.35-1.5 μM) and inhibits Pax2-DNA interactions. EG1 can inhibit embryonic kidney development, a process directly dependent on Pax2 activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.26%
- CAS No.: 693241-54-2
- Formule: C22H18N2O5
- Masse moléculaire:390.39
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) EG1
MoreVoir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
EG1 (0-12.5 μM; 48 hours) decreases viability in Pax2 positive renal cancer cell lines[1].
EG1 (0-500 μM) is capable of inhibiting Pax2 mediated expression of EGFP without significant effects on Pax2 protein levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Pax2 positive: a renal cell carcinoma line (RCC111), two ovarian carcinoma cell lines (TOV112D and ES-2); Pax2 negative: prostate cell lines 22Rv1, PC3 or the ovarian cancer cell line SK-OV-3
-
Concentration:0, 12.5, 25 μM
-
Incubation Time:48 hours
-
Result:All Pax2 positive cells exhibited a significant decrease in cell viability, whereas none of the Pax2 negative cells were affected.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 693241-54-2
-
Appearance Solid
-
Masse moléculaire 390.39
-
Formule C22H18N2O5
-
Color Off-white to yellow
-
SMILES
O=C(O)C1=CC=CC=C1NC(C2=CC=C(NC(C3=CC=CC=C3OC)=O)C=C2)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Mol Cell Biochem
PAX2 induces endometrial cancer by inhibiting mitochondrial function via the CD133-AKT1 pathway. [Abstract]2025 Jun;480(6):3765-3781. PMID: 39891863
Solvant et solubilité
DMSO : 83.33 mg/mL (213.45 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (5.33 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5615 mL | 12.8077 mL | 25.6154 mL | 64.0385 mL |
| 5 mM | 0.5123 mL | 2.5615 mL | 5.1231 mL | 12.8077 mL | |
| 10 mM | 0.2562 mL | 1.2808 mL | 2.5615 mL | 6.4039 mL | |
| 15 mM | 0.1708 mL | 0.8538 mL | 1.7077 mL | 4.2692 mL | |
| 20 mM | 0.1281 mL | 0.6404 mL | 1.2808 mL | 3.2019 mL | |
| 25 mM | 0.1025 mL | 0.5123 mL | 1.0246 mL | 2.5615 mL | |
| 30 mM | 0.0854 mL | 0.4269 mL | 0.8538 mL | 2.1346 mL | |
| 40 mM | 0.0640 mL | 0.3202 mL | 0.6404 mL | 1.6010 mL | |
| 50 mM | 0.0512 mL | 0.2562 mL | 0.5123 mL | 1.2808 mL | |
| 60 mM | 0.0427 mL | 0.2135 mL | 0.4269 mL | 1.0673 mL | |
| 80 mM | 0.0320 mL | 0.1601 mL | 0.3202 mL | 0.8005 mL | |
| 100 mM | 0.0256 mL | 0.1281 mL | 0.2562 mL | 0.6404 mL |
EG1 Related Classifications
HY-124838 Related Classifications
Powered by Bioz